Daiichi Sankyo plans to hack at least 1000 jobs
![](/46/pdcnewsitem/03/75/83/Daiichi.png)
The company reorganizes its US Commercial operations to support upcoming specialty pipeline.
Daiichi Sankyo will reorganize its US Commercial organization as it begins to transition from a maturing primary care product portfolio to a differentiated specialty portfolio that will include areas such as cardiovascular, pain management and oncology.
“As we face the loss of exclusivity in the coming year of our largest product, we also look ahead to great opportunities with our emerging portfolio in cardiology, oncology, fibromyalgia and pain relief,” said Ken Keller, President, US Commercial, Daiichi Sankyo, Inc. “This calls for us to restructure our organization into a smaller, highly targeted and efficient operating model, with a greater emphasis on customer-facing roles.”
As part of the reorganization, the company will reduce expenses, including a reduction in headcount, from its US Commercial operations. The company expects to eliminate 1,000 to 1,200 positions across the US Commercial function, through voluntary and involuntary displacements as well as eliminating open positions. The eliminated jobs will come from the US Commercial Home Office, located in Parsippany, New Jersey, as well as field-based sales and other positions throughout the country. This reorganization is not focused on US-based R&D functions, which have staff concentrated in Edison, NJ, or its packaging plant in Bethlehem, PA.
“Daiichi Sankyo recognizes the macro changes occurring in the US healthcare system that place a greater emphasis on managing the needs of patients with more complex healthcare needs. As a specialty company, we will be positioned to meet those needs and invest in advancing technologies that will make a significant difference in patient lives,” said Keller. “While this initiative will place us on the path toward long-term success, it does require us to make some difficult decisions. We are grateful for the contributions of all of our employees and are committed to making this process as easy and streamlined as possible for them through outplacement services and other support.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance